Gynecologic Oncology Program
The focus of the team of clinicians who form the Gynecologic Oncology Program at Smilow Cancer Hospital is to provide comprehensive and compassionate care for women with gynecologic cancers. Women diagnosed with vulvar, vaginal, cervical, uterine, fallopian tube, or ovarian cancers are provided with exceptional care from Yale’s experienced team of gynecologic oncologists at the hospital’s dedicated Women’s Center.
In addition, the team also treats soft tissue tumors of the pelvis, gestational trophoblastic disease, as well as women with precancerous changes that have been identified in the vulva, vagina, and cervix, including dysplasia and carcinoma in situ, or premalignant changes of the endometrium, including adenomatous hyperplasia.
Our Approach
The physicians of the Gynecologic Oncology Program offer a wide spectrum of advanced strategies for the diagnosis and treatment of gynecologic cancers, including colposcopy evaluation, conformal radiotherapy, and novel, targeted chemotherapies. The multidisciplinary program has experts from the obstetrics, gynecology, and reproductive sciences; radiation oncology; radiology and biomedical imaging; genetics; pathology; pharmacy; and social work. A dedicated patient coordinator facilitates patient appointments and communication, coordinates services, and supports each patient and their family.
Our Services
Surgery for previously untreated gynecologic cancer
Chemotherapy Management
Radiation Therapy
Radiology
Pathology
Surgery for benign disease
Surgery for complications
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
HIPEC is a technique that delivers high doses of heated chemotherapy directly to abdominal organs to kill cancer cells that may remain after surgical removal of visible tumors. Our physicians are national leaders in the delivery of HIPEC, with a deep understanding of the types of cancer it can be used to treat, the nuances of the therapy, and its effectiveness. Clinical trials using HIPEC are also available
Colposcopy
Discovery to Cure Program
Gynecologic Oncology Program Members
Survivor Stories
Fact Sheets
News
News from Gynecologic Oncology Program
Gynecological Cancer Trials
- Gynecological Cancers
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome
- Gynecological Cancers
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)
- Ages18 years - 99 years
- GenderFemale only